NTHI - NASDAQ
Neonc Technologies Holdings, Inc.
$4.35
-4.2%Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
At a Glance
Live SnapshotNeonc Technologies Holdings, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Neonc Technologies Holdings, Inc. Balance Sheet
NTHI • NASDAQ
| Neonc Technologies Holdings, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
58.7K | 64.9K | 31.9K | 633.3K | 25K | |
58.7K | 64.9K | 31.9K | 633.3K | 25K | |
0.0 | 148.7K | 0.0 | 0.0 | 0.0 | |
0.0 | 148.7K | 0.0 | 0.0 | 0.0 | |
583.1K | 386.6K | 262.9K | 95.4K | 7.5K | |
746.9K | 1.6M | 970.6K | 0.0 | 0.0 | |
1.4M | 2.2M | 1.3M | 728.7K | 32.5K | |
NON-CURRENT ASSETS | |||||
361K | 23.5K | 0.0 | 0.0 | 0.0 | |
500K | 0.0 | 0.0 | 0.0 | 0.0 | |
500K | 0.0 | 0.0 | 0.0 | 0.0 | |
573.9K | 1.2M | 0.0 | 0.0 | 0.0 | |
1.4M | 1.2M | 0.0 | 0.0 | 0.0 | |
2.8M | 3.4M | 1.3M | 728.7K | 32.5K | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
12M | 8.2M | 7.6M | 1.3M | 537.4K | |
7.1M | 3.5M | 3M | 1.3M | 537.4K | |
4.9M | 4.6M | 4.6M | 0.0 | 0.0 | |
1.8M | 0.0 | 0.0 | 412.5K | 0.0 | |
6M | 24.7K | 6.6M | 50K | 1.1M | |
71.1K | 24.7K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 500K | 500K | |
255.1K | 710.2K | 1.1M | 0.0 | 462.5K | |
20M | 8.9M | 15.3M | 2.3M | 2.6M | |
NON-CURRENT LIABILITIES | |||||
0.0 | -5K | 0.0 | 0.0 | 0.0 | |
290.7K | -5K | 0.0 | 0.0 | 0.0 | |
361.8K | 24.7K | 0.0 | 0.0 | 0.0 | |
20.3M | 8.9M | 15.3M | 2.3M | 2.6M | |
SHAREHOLDERS' EQUITY | |||||
-2.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 3K | |
2.2K | 1.8K | 1.7K | 1.1K | 56.7K | |
98M | 45.1M | 24.7M | 22.2M | 18.1M | |
-112.8M | -50.6M | -38.7M | -23.8M | -20.7M | |
-17.5M | -5.5M | -14M | -1.6M | -2.6M | |
-17.5M | -5.5M | -14M | -1.6M | -2.6M | |
SUMMARY | |||||
2.8M | 3.4M | 1.3M | 728.7K | 32.5K | |
6.3M | 24.7K | 6.6M | 50K | 1.1M | |
6.3M | -40.2K | 6.6M | -583.3K | 1.1M | |
19,279,118 | 19,279,118 | 19,279,118 | 19,279,118 | 19,279,118 |
SEC Filings
NTHI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | May 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
S-3 S-3 N/A | April 10, 2026 | April 10, 2026 | ||
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
S-3 S-3 N/A | April 02, 2026 | April 02, 2026 | ||
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your NTHI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.